Anovulatory, Infertility, Ovarian Function, Ovarian Reserve Markers
Conditions
Keywords
Shear Wave Elastography, Transvaginal Ultrasound, Ovarian Stroma, Anti-Mullerian Hormone
Brief summary
This study aims to evaluate the relationship between ovarian stromal stiffness measured by transvaginal shear wave elastography (SWE) and conventional hormonal and ultrasonographic parameters of ovarian reserve. Reproductive-aged female patients will be evaluated to determine whether tissue elasticity provided by SWE correlates with ovarian function markers such as anti-Müllerian hormone (AMH), antral follicle count (AFC), and ovarian volume.
Detailed description
Transvaginal ultrasound combined with shear wave elastography will be performed on all participants. Ovarian stromal stiffness values (measured in kilopascals or meters per second) will be correlated with basal serum hormone levels (AMH, FSH, LH, Estradiol) and ultrasonographic ovarian reserve criteria (antral follicle count and total ovarian volume).
Interventions
DIAGNOSTIC_TESTTransvaginal Shear Wave Elastography
Measurement of ovarian stromal elasticity using transvaginal shear wave elastography alongside standard ultrasound evaluation of antral follicle count and ovarian volume
Sponsors
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Female patients aged 18 to 45 years. * Regular menstrual cycles (21-35 days) or irregular menstruel cycles (oligo-anovaltion) * Normal pelvic anatomy on baseline ultrasound evaluation. * Written informed consent to participate in the study.
Exclusion criteria
* History of prior ovarian or adnexal surgery. * History of pelvic radiotherapy or chemotherapy. * Presence of structural pelvic/ovarian pathology (e.g., endometrioma, ovarian cyst, dermoid cyst, active pelvic inflammatory disease). * Use of hormonal contraceptives, ovulation induction agents, or hormone therapy within the last 3 months. * Pregnancy or current lactation. * Severe obesity or technical limitations preventing adequate transvaginal ultrasound and elastography imaging
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ovarian Stromal Elasticity Value | At the time of baseline ultrasound examination(Day 1) | Measurement of ovarian stromal tissue stiffness/elasticity using transvaginal shear wave elastography, expressed in kilopascals (kPa) or velocity (m/s). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum Anti- Mullerian Hormone (AMH) | At baseline (Day 1) | Measurement of Serum AMH concentration (ng/mL) to assess baseline ovarian reserve |
| Antral Follicle Count (AFC) | At baseline ultasound examination (Day 1) | Total number of antral follicles(measuring 2-10 mm) counted in both ovaries via transvaginal ultrasonography |
| Ovarian Volume | At baseline ultrasound examination(Day 1) | Measurement of ovarian volume (cm\^3) calculated using the prolate ellipsoid formula (length\*width\*height\*0,523) via transvaginal ultrasonography |
| Serum Follicle-Stimulating Hormone | at baseline (day 1) | Measurement of Basal serum FSH concentration (IU/L) evaluated in the early follicular phase (Day 2-4 of menstrual cycle) |
| Serum Luteinizing Hormone (LH) | at baseline (day 1) | Measurement of Basal Serum LH concentration (IU/L) evaluated in the early follicular phase (Day 2-4of menstruel cycle) |
| Serum Estradiol (E2) Levels | at baseline (day 1) | Measurement of basal serum estradiol concentration (pg/ml) evaluated in the early follicular phase (Day 2-4 of menstruel cycle) |
Countries
Turkey (Türkiye)
Contacts
CONTACTAbdullah ACAR, MD
PRINCIPAL_INVESTIGATORSerap M. ÖZÇELİK OTCU, MD, AssocProf.
University of Health Sciences Gazi Yasargil Training and Research Hospital, Dept. of OB/GYN
Outcome results
None listed